{"entity":{"id":"nct06787144","kind":"trial","name":"ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants","aka":[],"tldr":"A phase 1 trial of Relcobatinib run by Enliven Therapeutics, now recruiting.","summary":"ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants is a phase 1 interventional study registered as NCT06787144 by Enliven Therapeutics, with 21 participants planned, started 2025-01-23. Conditions recorded: CML (Chronic Myelogenous Leukemia) and Chronic Phase CML. Interventions recorded: ELVN-001.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06787144","url":"https://clinicaltrials.gov/study/NCT06787144"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml","cml-chronic-phase"],"sections":[],"technologies":[],"targets":[],"drugs":["relcobatinib"],"companies":["enliven-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06787144","phase":"1","setting":"A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants","sponsor":"Enliven Therapeutics","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06787144/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/"}],"drug":[{"id":"relcobatinib","kind":"drug","name":"Relcobatinib","route":"/drugs/relcobatinib/"}],"company":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/"}]}}